Portions of this exhibit have been omitted pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). The omitted portions, marked by [***], have been separately filed with the Securities and...Exclusive License and Supply Agreement • March 6th, 2018 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Supply Agreement (this “Agreement”) dated as of the 17th day of October, 2017 is made by and between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel (“Protalix”), and Chiesi Farmaceutici S.p.A., a company incorporated under the laws of Italy with offices located at Largo F. Belloli, 11/A - 43122 Parma, Italy (“Chiesi”) (each, a “Party” and collectively, the “Parties”).
